Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPowell, T.en
dc.contributor.authorMcGuffin, P.en
dc.contributor.authorD'Souza, U.en
dc.contributor.authorCohen-Woods, S.en
dc.contributor.authorHosang, G.en
dc.contributor.authorMartin, C.en
dc.contributor.authorMatthews, K.en
dc.contributor.authorDay, R.en
dc.contributor.authorFarmer, A.en
dc.contributor.authorTansey, K.en
dc.contributor.authorSchalkwyk, L.en
dc.identifier.citationPLoS One, 2014; 9(3):e91076-1-e91076-9en
dc.description.abstractMood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for transcriptional differences in a 'discovery cohort' (total n = 90) and then we use t-tests to assess the reliability of any identified transcriptional differences in a 'validation cohort' (total n = 35). The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used prospectively to aid clinical diagnosis.en
dc.description.statementofresponsibilityTimothy R. Powell, Peter McGuffin, Ursula M. D, Souza, Sarah Cohen-Woods, Georgina M. Hosang, Charlotte Martin, Keith Matthews, Richard K. Day, Anne E. Farmer, Katherine E. Tansey, Leonard C. Schalkwyken
dc.publisherPublic Library of Scienceen
dc.rights© 2014 Powell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.subjectHumans; Inflammation Mediators; Biological Markers; Cytokines; Diagnosis, Differential; Analysis of Variance; Risk Factors; Case-Control Studies; Reproducibility of Results; Gene Expression Profiling; Bipolar Disorder; Depressive Disorder, Major; Signal Transduction; Adult; Aged; Middle Aged; Female; Male; Receptors, CCR6; Chemokine CCL24; Transcriptomeen
dc.titlePutative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patientsen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidCohen-Woods, S. [0000-0003-2199-6129]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_94979.pdfPublished version398.7 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.